[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Colchicine in the management of mucous membrane pemphigoid

Dermatol Ther. 2011 Jul-Aug;24(4):443-5. doi: 10.1111/j.1529-8019.2011.01438.x.

Abstract

Mucous membrane pemphigoid (MMP) usually runs a chronic and potentially devastating course. Its management requires long-term oral corticosteroids. Safe and effective adjuvant or steroid-sparing agents are needed. In this retrospective observational study with a follow-up extending to 16 years (mean: 4 years), 60% (9/15) of all patients with MMP were lesion-free under oral steroid therapy combined with a second immunosuppressant agent. Colchicine was the most effective, clearing from at least one individual mucosal site lesions in 67% (8/12) of patients. Colchicine may be suggested as a first-line corticosteroid-sparing regimen in the management of MMP.

MeSH terms

  • Adult
  • Aged
  • Colchicine / therapeutic use*
  • Female
  • Follow-Up Studies
  • Glucocorticoids / adverse effects
  • Glucocorticoids / therapeutic use
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Male
  • Middle Aged
  • Pemphigoid, Benign Mucous Membrane / drug therapy*
  • Pemphigoid, Benign Mucous Membrane / pathology
  • Retrospective Studies
  • Treatment Outcome
  • Tubulin Modulators / therapeutic use*

Substances

  • Glucocorticoids
  • Immunosuppressive Agents
  • Tubulin Modulators
  • Colchicine